Trial Endpoint Met—and Exceeded—in Medtronic’s Implant Cardioverter Defibrillator Trial

Having designed it to deal with the hazardously accelerated heart rhythms that can cause sudden cardiac arrest (SCA), medtech mainstay Medtronic’s investigation EV ICD (extravascular implantable cardioverter defibrillator) system has now met trial endpoints. Results from its testing phase were presented at the European Society of Cardiology (ESC) Congress 2022 in Barcelona as well as laid out in The New England Journal of Medicine...